Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

ADAMTS13 Deficiency Shortens the Lifespan of Mice with Experimental Diabetes.

Cassis P, Cerullo D, Zanchi C, Corna D, Lionetti V, Giordano F, Novelli R, Conti S, Casieri V, Matteucci M, Locatelli M, Taraboletti G, Villa S, Gastoldi S, Remuzzi G, Benigni A, Zoja C.

Diabetes. 2018 Jul 5. pii: db171508. doi: 10.2337/db17-1508. [Epub ahead of print]

PMID:
29976618
2.

Soluble stroma-related biomarkers of pancreatic cancer.

Resovi A, Bani MR, Porcu L, Anastasia A, Minoli L, Allavena P, Cappello P, Novelli F, Scarpa A, Morandi E, Falanga A, Torri V, Taraboletti G, Belotti D, Giavazzi R.

EMBO Mol Med. 2018 Jun 25. pii: e8741. doi: 10.15252/emmm.201708741. [Epub ahead of print]

3.

Thrombospondin-1 promotes mesenchymal stromal cell functions via TGFβ and in cooperation with PDGF.

Belotti D, Capelli C, Resovi A, Introna M, Taraboletti G.

Matrix Biol. 2016 Sep;55:106-116. doi: 10.1016/j.matbio.2016.03.003. Epub 2016 Mar 16.

PMID:
26992552
4.

Snail levels control the migration mechanism of mesenchymal tumor cells.

Belgiovine C, Chiesa G, Chiodi I, Frapolli R, Bonezzi K, Taraboletti G, D'Incalci M, Mondello C.

Oncol Lett. 2016 Jul;12(1):767-771. Epub 2016 May 30.

5.

PO-15 - Antiangiogenic small molecule ligands of FGF2 derived from the endogenous inhibitor thrombospondin-1.

Pinessi D, Foglieni C, Bugatti A, Moroni E, Resovi A, Ribatti D, Rusnati M, Giavazzi R, Colombo G, Taraboletti G.

Thromb Res. 2016 Apr;140 Suppl 1:S182. doi: 10.1016/S0049-3848(16)30148-7. Epub 2016 Apr 8.

PMID:
27161705
6.

Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors.

Foglieni C, Pagano K, Lessi M, Bugatti A, Moroni E, Pinessi D, Resovi A, Ribatti D, Bertini S, Ragona L, Bellina F, Rusnati M, Colombo G, Taraboletti G.

Sci Rep. 2016 Mar 22;6:23432. doi: 10.1038/srep23432.

7.

Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.

Decio A, Cesca M, Bizzaro F, Porcu L, Bettolini R, Ubezio P, Taraboletti G, Belotti D, Giavazzi R.

Clin Exp Metastasis. 2015 Oct;32(7):647-58. doi: 10.1007/s10585-015-9734-1. Epub 2015 Jul 17.

PMID:
26185056
8.

Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.

Pinessi D, Ostano P, Borsotti P, Bello E, Guffanti F, Bizzaro F, Frapolli R, Bani MR, Chiorino G, Taraboletti G, Resovi A.

Connect Tissue Res. 2015;56(5):355-63. doi: 10.3109/03008207.2015.1045065. Epub 2015 Jun 15.

PMID:
25943461
9.

Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.

Borsotti P, Ghilardi C, Ostano P, Silini A, Dossi R, Pinessi D, Foglieni C, Scatolini M, Lacal PM, Ferrari R, Moscatelli D, Sangalli F, D'Atri S, Giavazzi R, Bani MR, Chiorino G, Taraboletti G.

Pigment Cell Melanoma Res. 2015 Jan;28(1):73-81. doi: 10.1111/pcmr.12319. Epub 2014 Oct 13.

PMID:
25256553
10.

Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.

Dossi R, Frapolli R, Di Giandomenico S, Paracchini L, Bozzi F, Brich S, Castiglioni V, Borsotti P, Belotti D, Uboldi S, Sanfilippo R, Erba E, Giavazzi R, Marchini S, Pilotti S, D'Incalci M, Taraboletti G.

Int J Cancer. 2015 Feb 1;136(3):721-9. doi: 10.1002/ijc.29023. Epub 2014 Jun 19.

11.

Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms.

Decio A, Taraboletti G, Patton V, Alzani R, Perego P, Fruscio R, Jürgensmeier JM, Giavazzi R, Belotti D.

Am J Pathol. 2014 Apr;184(4):1050-1061. doi: 10.1016/j.ajpath.2013.12.030. Epub 2014 Feb 6. Erratum in: Am J Pathol. 2014 Jul;184(7):2144.

PMID:
24508126
12.

Current understanding of the thrombospondin-1 interactome.

Resovi A, Pinessi D, Chiorino G, Taraboletti G.

Matrix Biol. 2014 Jul;37:83-91. doi: 10.1016/j.matbio.2014.01.012. Epub 2014 Jan 27. Review.

13.

Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.

Zucchetti M, Bonezzi K, Frapolli R, Sala F, Borsotti P, Zangarini M, Cvitkovic E, Noel K, Ubezio P, Giavazzi R, D'Incalci M, Taraboletti G.

Cancer Chemother Pharmacol. 2013 Oct;72(4):879-87. doi: 10.1007/s00280-013-2270-2. Epub 2013 Aug 24.

PMID:
23978989
14.

The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.

Bello E, Taraboletti G, Colella G, Zucchetti M, Forestieri D, Licandro SA, Berndt A, Richter P, D'Incalci M, Cavalletti E, Giavazzi R, Camboni G, Damia G.

Mol Cancer Ther. 2013 Feb;12(2):131-40. doi: 10.1158/1535-7163.MCT-12-0275-T. Epub 2012 Dec 27.

15.

Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies.

Bonezzi K, Belotti D, North BJ, Ghilardi C, Borsotti P, Resovi A, Ubezio P, Riva A, Giavazzi R, Verdin E, Taraboletti G.

Neoplasia. 2012 Sep;14(9):846-54.

16.

Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule.

Pagano K, Torella R, Foglieni C, Bugatti A, Tomaselli S, Zetta L, Presta M, Rusnati M, Taraboletti G, Colombo G, Ragona L.

PLoS One. 2012;7(5):e36990. doi: 10.1371/journal.pone.0036990. Epub 2012 May 14.

17.

Targeting angiogenesis with compounds from the extracellular matrix.

Belotti D, Foglieni C, Resovi A, Giavazzi R, Taraboletti G.

Int J Biochem Cell Biol. 2011 Dec;43(12):1674-85. doi: 10.1016/j.biocel.2011.08.012. Epub 2011 Aug 17. Review.

PMID:
21864705
18.
19.

Reduced expression of the ROCK inhibitor Rnd3 is associated with increased invasiveness and metastatic potential in mesenchymal tumor cells.

Belgiovine C, Frapolli R, Bonezzi K, Chiodi I, Favero F, Mello-Grand M, Dei Tos AP, Giulotto E, Taraboletti G, D'Incalci M, Mondello C.

PLoS One. 2010 Nov 30;5(11):e14154. doi: 10.1371/journal.pone.0014154.

20.

Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.

Rusnati M, Urbinati C, Bonifacio S, Presta M, Taraboletti G.

Pharmaceuticals (Basel). 2010 Apr 23;3(4):1241-1278. Review.

21.

Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds.

Colombo G, Margosio B, Ragona L, Neves M, Bonifacio S, Annis DS, Stravalaci M, Tomaselli S, Giavazzi R, Rusnati M, Presta M, Zetta L, Mosher DF, Ribatti D, Gobbi M, Taraboletti G.

J Biol Chem. 2010 Mar 19;285(12):8733-42. doi: 10.1074/jbc.M109.085605. Epub 2010 Jan 7.

22.

Vascular disrupting activity of tubulin-binding 1,5-diaryl-1H-imidazoles.

Bonezzi K, Taraboletti G, Borsotti P, Bellina F, Rossi R, Giavazzi R.

J Med Chem. 2009 Dec 10;52(23):7906-10. doi: 10.1021/jm900968s.

PMID:
19954252
23.

Cathepsin B mediates the pH-dependent proinvasive activity of tumor-shed microvesicles.

Giusti I, D'Ascenzo S, Millimaggi D, Taraboletti G, Carta G, Franceschini N, Pavan A, Dolo V.

Neoplasia. 2008 May;10(5):481-8.

24.

Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion.

Belotti D, Calcagno C, Garofalo A, Caronia D, Riccardi E, Giavazzi R, Taraboletti G.

Mol Cancer Res. 2008 Apr;6(4):525-34. doi: 10.1158/1541-7786.MCR-07-0366.

25.

Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain.

Margosio B, Rusnati M, Bonezzi K, Cordes BL, Annis DS, Urbinati C, Giavazzi R, Presta M, Ribatti D, Mosher DF, Taraboletti G.

Int J Biochem Cell Biol. 2008;40(4):700-9. Epub 2007 Oct 9.

26.

Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds.

Giavazzi R, Bani MR, Taraboletti G.

Cancer Metastasis Rev. 2007 Dec;26(3-4):481-8. Review.

PMID:
17896168
27.

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel.

Martinelli M, Bonezzi K, Riccardi E, Kuhn E, Frapolli R, Zucchetti M, Ryan AJ, Taraboletti G, Giavazzi R.

Br J Cancer. 2007 Oct 8;97(7):888-94. Epub 2007 Sep 11.

28.

Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development.

Kruczynski A, Poli M, Dossi R, Chazottes E, Berrichon G, Ricome C, Giavazzi R, Hill BT, Taraboletti G.

Eur J Cancer. 2006 Nov;42(16):2821-32. Epub 2006 Sep 14.

PMID:
16973349
29.

Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH.

Taraboletti G, D'Ascenzo S, Giusti I, Marchetti D, Borsotti P, Millimaggi D, Giavazzi R, Pavan A, Dolo V.

Neoplasia. 2006 Feb;8(2):96-103.

30.

Gorham-Stout syndrome: a monocyte-mediated cytokine propelled disease.

Colucci S, Taraboletti G, Primo L, Viale A, Roca C, Valdembri D, Geuna M, Pagano M, Grano M, Pogrel AM, Harris AL, Athanasou NN, Mantovani A, Zallone A, Bussolino F.

J Bone Miner Res. 2006 Feb;21(2):207-18. Epub 2005 Oct 31.

31.

Shedding of membrane vesicles by tumor and endothelial cells.

Dolo V, D'Ascenzo S, Giusti I, Millimaggi D, Taraboletti G, Pavan A.

Ital J Anat Embryol. 2005;110(2 Suppl 1):127-33.

PMID:
16101030
32.

Potential antagonism of tubulin-binding anticancer agents in combination therapies.

Taraboletti G, Micheletti G, Dossi R, Borsotti P, Martinelli M, Fiordaliso F, Ryan AJ, Giavazzi R.

Clin Cancer Res. 2005 Apr 1;11(7):2720-6.

33.

Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells.

Scarpino S, Di Napoli A, Taraboletti G, Cancrini A, Ruco LP.

J Pathol. 2005 Jan;205(1):50-6.

PMID:
15526350
34.

45th annual meeting of the Italian Cancer Society. Bergamo, 9-12 November 2003.

Giavazzi R, Aglietta M, Astolfi A, Falanga A, Fusco A, Labianca R, Lollini PL, Lombardo C, Natali PG, Pierotti MA, Presta M, Santoro M, Taraboletti G, Zupi G, Vecchio G.

Tumori. 2004 May-Jun;90(3):356-62.

PMID:
15315322
35.

Antiangiogenic activity of aplidine, a new agent of marine origin.

Taraboletti G, Poli M, Dossi R, Manenti L, Borsotti P, Faircloth GT, Broggini M, D'Incalci M, Ribatti D, Giavazzi R.

Br J Cancer. 2004 Jun 14;90(12):2418-24.

36.

Modelling approaches for angiogenesis.

Taraboletti G, Giavazzi R.

Eur J Cancer. 2004 Apr;40(6):881-9. Review.

PMID:
15120043
37.

ERK1-2 and p38 MAPK regulate MMP/TIMP balance and function in response to thrombospondin-1 fragments in the microvascular endothelium.

Donnini S, Morbidelli L, Taraboletti G, Ziche M.

Life Sci. 2004 Apr 30;74(24):2975-85.

PMID:
15051421
38.

Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation.

Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R.

Cancer Res. 2003 Sep 1;63(17):5224-9.

39.

Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2.

Margosio B, Marchetti D, Vergani V, Giavazzi R, Rusnati M, Presta M, Taraboletti G.

Blood. 2003 Dec 15;102(13):4399-406. Epub 2003 Aug 28.

40.

Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.

Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, Taraboletti G, Labianca R, Belotti D, Giavazzi R.

Eur J Cancer. 2003 Sep;39(13):1948-56.

PMID:
12932675
41.

IDN 5390: a new concept in taxane development.

Taraboletti G, Micheletti G, Giavazzi R, Riva A.

Anticancer Drugs. 2003 Apr;14(4):255-8. Review.

PMID:
12679728
42.

Vascular-targeting activity of ZD6126, a novel tubulin-binding agent.

Micheletti G, Poli M, Borsotti P, Martinelli M, Imberti B, Taraboletti G, Giavazzi R.

Cancer Res. 2003 Apr 1;63(7):1534-7.

43.

Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.

Broggini M, Marchini SV, Galliera E, Borsotti P, Taraboletti G, Erba E, Sironi M, Jimeno J, Faircloth GT, Giavazzi R, D'Incalci M.

Leukemia. 2003 Jan;17(1):52-9.

PMID:
12529660
44.

Thrombospondin-1: an inhibitor of angiogenesis.

Taraboletti G.

Haemostasis. 2001;31 Suppl 1:23-4. No abstract available.

PMID:
11990468
45.

Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.

Taraboletti G, Micheletti G, Rieppi M, Poli M, Turatto M, Rossi C, Borsotti P, Roccabianca P, Scanziani E, Nicoletti MI, Bombardelli E, Morazzoni P, Riva A, Giavazzi R.

Clin Cancer Res. 2002 Apr;8(4):1182-8.

46.

Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells.

Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V.

Am J Pathol. 2002 Feb;160(2):673-80.

47.

Antiangiogenic and antivascular therapy for cancer.

Taraboletti G, Margosio B.

Curr Opin Pharmacol. 2001 Aug;1(4):378-84. Review.

PMID:
11710736
48.

p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis.

Vikhanskaya F, Bani MR, Borsotti P, Ghilardi C, Ceruti R, Ghisleni G, Marabese M, Giavazzi R, Broggini M, Taraboletti G.

Oncogene. 2001 Nov 1;20(50):7293-300.

49.

Preclinical development of metalloproteasis inhibitors in cancer therapy.

Giavazzi R, Taraboletti G.

Crit Rev Oncol Hematol. 2001 Jan;37(1):53-60. Review.

PMID:
11164719
50.

Inhibition of matrix metalloproteinases by over-expression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas.

Vergani V, Garofalo A, Bani MR, Borsotti P, Parker MP, Drudis T, Mazzarol G, Viale G, Giavazzi R, Stetler-Stevenson WG, Taraboletti G.

Int J Cancer. 2001 Jan 15;91(2):241-7.

Supplemental Content

Loading ...
Support Center